TLV subsidises anti-viral treatment of COVID-19 to risk groups

21 November 2022 - Paxlovid, which treats patients who are at risk of becoming seriously ill from COVID-19, will be ...

Read more →

TLV subsidises drugs against cystic fibrosis

18 November 2022 - The Dental and Pharmaceutical Benefits Agency, TLV, has decided that the drugs Kaftrio, Kalydeco and Symkevi, ...

Read more →

This is how access to older antibiotics can be strengthened

14 November 2022 - Shortages in access to antibiotics can pose serious obstacles to responsible antibiotic treatment - and a survey ...

Read more →

Continued development of the national health data registers leads to better follow-up of medicines

3 October 2022 - The Dental and Pharmaceutical Benefits Agency (TLV) is today handing over a report to the government on ...

Read more →

Exits from pharmaceutical benefits on 1 October 2022

8 September 2022 - Below is a compilation of the medicines in different packaging sizes which, at the companies' own ...

Read more →

New handbook on health economic assessments of medical devices

18 August 2022 - TLV carries out health economic assessments of medical technology products at the request of the Medical Technology ...

Read more →

TLV reconsiders Orkambi's subsidy

4 July 2022 - TLV has started a reconsideration of the drug Orkambi in light of the fact that the ...

Read more →

TLV receives assignments for medicines for rare diseases

27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to analyse and make ...

Read more →

TLV receives a new assignment on precision medicine and ATMP

27 June 2022 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency (TLV) to continue the work ...

Read more →

Zeposia is included in the high-cost protection with limitation

17 June 2022 - Zeposia (ozanimod) is included in the high-cost protection with limited subsidy from 17 June 2022.  ...

Read more →

Givlaari is included in the high-cost protection with limitation

17 June 2022 - Givlaari (givosiran) is included in the high-cost protection with limited subsidy to reduce attacks in patients with ...

Read more →

Subsidy for medicine for Duchenne muscular dystrophy expires

16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not ...

Read more →

TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios

8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...

Read more →

TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors

2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...

Read more →

Health economic assessment of Trodelvy in advanced triple negative breast cancer

23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan).  ...

Read more →